CA 15-3 Method: ECLIA, Roche (Serum (s))
| Specimens: | 500 µl Serum (s) |
| Preanalytics/Notes: | In patients receiving therapy with high biotin doses (i.e. > 5 mg/day) no sample should be taken until at least 8 hours after the last biotin administration, as high dosis biotin application might disturbe the assay. |
| Method: | ECLIA |
| Dimension: | U/ml |
| Set-up: | Mon Tue Wed Thu Fri Sat Sun |
| Duration: | 1 day |
| Indication/Significance: | Tumour marker for the follow up in the case of mammary carcinoma (not suitable for screening or early diagnosis!), for tumour follow-up together with CEA |
| Interpretation: |
CA 15-3 is the best more… CA 15-3 is the best marker for the follow up of metastasing mammary carcinoma. In the case of a detected mammary carcinoma, the marker is also of prognostic relevance, but it is not suitable for diagnosing or for screening purposes due to frequently elevated levels in many other malignomas (ovarian carcinoma, pulmonary carcinoma, gastric carcinoma, pancreatic carcinoma and others) and also in benign mammary diseases (e.g. mastopathy). In patients with curative operable tumour without metastasing, elevated levels are only found in approx. 20 - 30 %. The biological half-life is 5 to 7 days. The additional determination of CEA is recommended. see table under keyword "tumour marker" |
| Further tests: | CEA |
performance by Bioscientia medical service centers
Reference range / valuation (openclose)
| both sex | ||
|---|---|---|
| < 25,0 U/ml | ||
initial letter
Abrechnung GOÄ
Die Kosten werden für den i. d. R. genutzten 1,15-fachen GOÄ-Satz dargestellt. Wird die Untersuchung nicht in Ihrem regionalen Labor durchgeführt, erfolgt die Analyse in dem Labor, das im Leistungsverzeichnis genannt ist. In diesem Fall gilt der dort für die Untersuchung angegebene Preis.